FNDC3B and cholangiocarcinoma: In addition to PC, Wilcoxon rank sum test demonstrated higher expression levels of FNDC3B in bladder urothelial carcinoma, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma multiforme, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, acute myeloid leukemia, brain lower grade glioma hepatocellular carcinoma liver, lung adenocarcinoma squamous cell carcinoma lung rectum adenocarcinoma skin cutaneous melanoma stomach adenocarcinoma testicular germ cell tumor uterine corpus endometrial carcinoma (P < 0.05, Fig. 1B).